MeSH D014890 - granulomatosis with polyangiitis
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Teva | Cyclophosphamide | Neosar |  | 1993-04-29 |  |  |
| Dr Reddys Laboratories | Cyclophosphamide | Cyclophosphamide | 2036-02-15 | 2020-07-30 |  |  |
| Roche | Rituximab | MabThera |  | 1998-06-02 |  |  |
| Cipla | Cyclophosphamide | Cyclophosphamide |  | 2019-01-18 |  |  |
| Sandoz | Rituximab | Rixathon |  | 2017-06-15 |  |  |
| Rituximab | Riximyo |  | 2017-06-15 |  |  | |
| Cyclophosphamide | Cyclophosphamide |  | 2023-09-12 |  |  | |
| Pfizer | Rituximab | Ruxience |  | 2019-07-23 | $390 M | Y2023 |
| Alembic Pharmaceuticals | Cyclophosphamide | Cyclophosphamide |  | 2022-11-10 |  |  |
| Amneal Pharmaceuticals | Cyclophosphamide | Cyclophosphamide |  | 2018-05-25 |  |  |
| Biogen | Rituximab | Rituxan |  | 2002-02-19 |  |  |
| ANI Pharmaceuticals | Cyclophosphamide | Cyclophosphamide |  | 2018-03-19 |  |  |
1
2
3
>
Clinical Trials
Historical Success Rate
Phase 1
100%7/7
Phase 2
70%16/23
Phase 3
57%16/28
Approved: 4Overall Success rate: 40%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
1
2
>
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use